Adjunctive therapy for severe
acne. Redesigned with
patients in mind.

Doryx® MPC—engineered to further delay the release of doxycycline

  • The modified polymer coat (MPC) of Doryx® MPC delays drug release by approximately 15 to 20 minutes farther into the GI tract1-3
    • — Minimizes upper GI tract exposure to doxycycline
  • Doryx® MPC 120 mg is bioequivalent to Doryx® 100 mg2
    • — The further-delayed release of Doryx® MPC results in approximately 86% bioavailability of doxycycline

Immediate Release

Formulated to release immediately after ingestion

Acticlate® (doxycycline hyclate USP) Tablets*

Extended Release

Formulated to extend systemic
blood levels

Solodyn® (minocycline HCl, USP) Extended Release Tablets

Delayed Release

Formulated to further delay the
release of drug farther into the GI tract

Doryx® MPC (doxycycline hyclate delayed-release tablets)

*Acticlate is a registered trademark of Aqua Pharmaceuticals, LLC.

Solodyn is a registered trademark of Valeant Pharmaceuticals International, Inc.

Back to top

Doryx® MPC tablets contain enteric-coated pellets for a 2-step release process

  • The modified polymer coat (MPC) of Doryx® MPC minimizes doxycycline exposure in the upper GI tract, including the esophagus and stomach
  • The MPC delays drug absorption by approximately 15 to 20 minutes farther in the GI tract1-3
Doryx MPC tablet

Enteric coating is more resistant to acidic pH levels found in the stomach

Step 1 in release process

The tablet vehicle of Doryx® MPC starts to dissolve

Step 2 in release process

The enteric-coated pellets containing doxycycline release and start to dissolve

Timing and location of release may vary from patient to patient.

Back to top

Doryx® MPC 120 mg tablets are bioequivalent to Doryx® 100 mg tablets1

Study design: Open-label, randomized, single-dose, 2-period, 2-treatment, 2-sequence, crossover study under fasting conditions in adults (N=28) comparing Doryx® MPC 120 mg to Doryx® 100 mg.

Serum concentrations of Doryx® MPC 120 mg compared with Doryx® 100 mg

Doryx MPC dosage graph

LLOQ=lower limit of quantification

Comparable bioequivalence under fasting and nonfasting conditions


Marginal loss of absorption mitigated by slight dose increase

Mean concentration values below LLOQ (<0.1 mcg/mL) in the terminal phase are not plotted.

Back to top

Doryx® MPC offers flexible dosing options2

Doryx MPC bottle
Doryx MPC prescription

QD
Doryx® MPC 120 mg for 100 mg of doxycycline/day


BID
Doryx® MPC 120 mg for 200 mg of doxycycline/day for severe infections

HCPs: For Doryx® MPC samples, please call
1-800-344-8661 to speak to a representative.

Patients: Talk to your doctor today to see if
Doryx® MPC is the right treatment option for you.

Back to top

Most insured, eligible patients pay $0 for Doryx® MPC!

Get instant savings on Doryx® MPC at participating retail and specialty pharmacies

  • Most eligible patients pay $0 and no more than $45
  • When e-prescribing, make sure all information for Doryx® MPC appears as it does on the example savings card
  • No activation required

Restrictions and limitations apply. Please see Terms, Conditions, and Eligibility Criteria of Doryx® MPC Patient Savings Program.

Copay Card
Back to top

INDICATION AND USAGE

Doryx® MPC (doxycycline hyclate delayed-release tablets) is a tetracycline-class antimicrobial indicated as adjunctive therapy for severe acne. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of Doryx® MPC and other antibacterial drugs, Doryx® MPC should be used only as indicated.

The usual dosage of Doryx® MPC is 240 mg on the first day of treatment (administered 120 mg every 12 hours) followed by a maintenance dose of 120 mg daily.

IMPORTANT SAFETY INFORMATION

Doxycycline is contraindicated in patients who have shown hypersensitivity to any of the tetracyclines. Tetracycline-class drugs, like Doryx® MPC (doxycycline hyclate delayed-release tablets), can cause fetal harm when administered to a pregnant woman. Doryx® MPC should be avoided if possible by nursing mothers, taking into account the importance of the drug to the mother. Doryx® MPC should not be used in children during tooth development (up to the age of 8 years). Concurrent use of tetracycline-class antibiotics with oral contraceptives may reduce their effectiveness.

Clostridium difficile associated diarrhea (CDAD) has been reported with nearly all antibacterial agents including doxycycline, and may range from mild diarrhea to fatal colitis.

Photosensitivity can occur with tetracycline-class drugs. Doryx® MPC patients should minimize or avoid excessive exposure to natural or artificial sunlight, and consider using sunscreen or sunblock. Advise patients to discontinue therapy at the first evidence of skin erythema.

Overgrowth of non-susceptible organisms, including fungi, may occur. Doryx® MPC should be discontinued if superinfection occurs and appropriate therapy instituted.

Intracranial Hypertension (IH) has been associated with the use of tetracyclines. Women of childbearing age who are overweight or have a history of IH are at greater risk for developing tetracycline-associated IH.

Adverse reactions observed in patients receiving tetracyclines include anorexia, nausea, vomiting, diarrhea, rash, photosensitivity, urticaria, and hemolytic anemia.

To report a suspected adverse reaction from one of our products, please contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please see full Prescribing Information here.

References: 1. Data on file. Greenville, NC; Mayne Pharma. 2. Doryx MPC [package insert]. Greenville, NC: Mayne Pharma; 2016. 3. Kircik LH, Bikowski JB. Enteric-coated doxycycline pellets, delayed release, in tablets. Pract Dermatol. 2010;(suppl):5-8.